ALPMY News and Press, Astellas Pharma Inc. ADR From 02/06/24

Astellas Makes Announcement about Management Structure PR Newswire TOKYO , Feb. 6, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced the following changes to its management stru...

2024-02-05 13:08:05 ET Astellas Pharma Inc. (ALPMF) Q3 2023 Results Earnings Conference Call February 5, 2024, 02:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief Financial Officer Tadaaki Taniguchi...

Kimball Electronics Inc. (KE) is expected to report $0.37 for Q2 2024 Sturgis Bancorp Inc (STBI) is expected to report for Q4 2023 Simon Property Group Inc. (SPG) is expected to report $3.34 for Q4 2023 Cabot Corporation (CBT) is expected to report $1.49 for Q1 2024 ChampionX Corp...

Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl PR Newswire Astellas is returning to the Super Bowl to help educate game viewers about VEOZAH and vasomotor symptoms (VMS), the most commonly reported menopause symptoms 1 The "Fewer Hot ...

2024-01-31 02:12:52 ET More on Astellas Pharma ADR FDA denies approval of Astellas gastric cancer drug Astellas and Elpiscience collaborate for novel bi-specific macrophage engagers Read the full article on Seeking Alpha For further details see: Astellas ...

Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer PR Newswire – Pivotal trial fo...

Astellas Announces Strategic Collaboration with Mass General Brigham PR Newswire - Five-year collaboration to advance translational medicine and accelerate early development of novel therapies - - Focus on oncology, rare disease, and cell and gene therapies - TOKYO...

2024-01-26 12:58:45 ET More on Merck Merck & Co., Inc. (MRK) JPMorgan 42nd Annual Healthcare Conference (Slides) Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript) Merck's Soaring Stock: Examining The Euphoria Amidst P...

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire – Pivotal trial found the enfortumab vedotin plus pembr...

2024-01-26 07:39:18 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - E...